Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study.

NASH is the second cause with an increasing trend and is also progressively emerging as an indication for LT in patients without HCC, only second in growth to ALD. 6 A recent international consensus, achieved through the Delphi method, introduced a new definition of steatotic liver diseases (SLDs), replacing the previous definitions of NAFLD and metabolic-[dysfunction] associated fatty liver disease (MAFLD).

also in 63,971 other papers